This included inhibitors used in the treatment of depression (imipramine and atomoxetine) and attention-deficit hyperactivity disorder (atomoxetine), a smoking cessation agent (bupropion), a psychostimulant drug (cocaine), and pharmacological tool compounds with selectivity for NET (nisoxetine and talopram) or DAT (GBR 12,909, JHW 007 and rimcazole). The gene discussed is SLC6A2; the disease is depressive symptom measurement.